KR20220002488A - 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법 - Google Patents

아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법 Download PDF

Info

Publication number
KR20220002488A
KR20220002488A KR1020217038511A KR20217038511A KR20220002488A KR 20220002488 A KR20220002488 A KR 20220002488A KR 1020217038511 A KR1020217038511 A KR 1020217038511A KR 20217038511 A KR20217038511 A KR 20217038511A KR 20220002488 A KR20220002488 A KR 20220002488A
Authority
KR
South Korea
Prior art keywords
day
substituted
dioxo
methylsulfonyl
acetamide
Prior art date
Application number
KR1020217038511A
Other languages
English (en)
Korean (ko)
Inventor
피터 헨리 섀퍼
로버트 플렌지
메리 애덤스
리사 비비
길레스 부흐발터
티파니 카르
테-첸 쳉
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20220002488A publication Critical patent/KR20220002488A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217038511A 2019-04-30 2019-04-30 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법 KR20220002488A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
KR20220002488A true KR20220002488A (ko) 2022-01-06

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217038511A KR20220002488A (ko) 2019-04-30 2019-04-30 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법
KR1020217038512A KR20220002489A (ko) 2019-04-30 2020-04-30 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217038512A KR20220002489A (ko) 2019-04-30 2020-04-30 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법

Country Status (14)

Country Link
EP (2) EP3962475A1 (es)
JP (2) JP2022537877A (es)
KR (2) KR20220002488A (es)
CN (2) CN114269336A (es)
AU (2) AU2019443366A1 (es)
BR (2) BR112021021809A2 (es)
CA (2) CA3138473A1 (es)
CL (1) CL2021002847A1 (es)
CO (2) CO2021015622A2 (es)
IL (2) IL287665A (es)
MA (1) MA55799A (es)
MX (2) MX2021013317A (es)
SG (2) SG11202112043PA (es)
WO (2) WO2020222773A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
TW202246232A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Ｔｙｋ２抑制劑及其用途
AU2022350509A1 (en) * 2021-09-23 2024-04-04 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012149251A1 (en) * 2011-04-28 2012-11-01 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
UA113750C2 (xx) 2011-12-27 2017-03-10 Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
RU2627661C2 (ru) 2012-01-10 2017-08-09 Ф. Хоффманн-Ля Рош Аг Соединения пиридазинамида и их применение в качестве ингибиторов тирозинкиназы селезенки (syk)
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US9296725B2 (en) 2012-05-24 2016-03-29 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
UY35126A (es) 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
EA028052B1 (ru) * 2012-11-08 2017-10-31 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
WO2014151180A1 (en) * 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
EP3029031A4 (en) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015032423A1 (en) 2013-09-03 2015-03-12 Sareum Limited Pharmaceutical compounds
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
CN105992768B (zh) 2013-12-10 2018-04-20 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
ES2921874T3 (es) 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
NO2721710T3 (es) 2014-08-21 2018-03-31
WO2016047678A1 (ja) 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
DK3419978T3 (da) 2016-02-24 2020-06-02 Pfizer Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
ES2902995T3 (es) 2016-10-07 2022-03-30 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018081488A1 (en) 2016-10-28 2018-05-03 Bristol-Myers Squibb Company Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
CN110191887B (zh) 2016-11-17 2022-02-18 百时美施贵宝公司 IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TW202321243A (zh) * 2017-03-08 2023-06-01 美商林伯士拉克許米公司 Ｔｙｋ２抑制劑之生產方法
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
KR20220002489A (ko) 2022-01-06
CL2021002847A1 (es) 2022-07-22
CA3138473A1 (en) 2020-11-05
JP7453251B2 (ja) 2024-03-19
IL287670A (en) 2021-12-01
EP3962476A1 (en) 2022-03-09
IL287665A (en) 2022-07-01
MA55799A (fr) 2022-03-09
AU2020266143A1 (en) 2021-12-02
CN114206333A (zh) 2022-03-18
JP2022537877A (ja) 2022-08-31
MX2021013317A (es) 2022-01-18
CA3138686A1 (en) 2020-11-05
MX2021013318A (es) 2022-01-31
SG11202112018YA (en) 2021-11-29
EP3962475A1 (en) 2022-03-09
AU2019443366A1 (en) 2021-12-02
WO2020222773A1 (en) 2020-11-05
BR112021021809A2 (pt) 2022-01-04
BR112021021826A2 (pt) 2022-01-04
CN114269336A (zh) 2022-04-01
BR112021021826A8 (pt) 2022-06-21
WO2020223431A1 (en) 2020-11-05
CO2021015614A2 (es) 2021-12-10
SG11202112043PA (en) 2021-11-29
JP2022537878A (ja) 2022-08-31
CO2021015622A2 (es) 2022-02-28

Similar Documents

Publication Publication Date Title
KR20220002489A (ko) 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법
US11357775B2 (en) Combination therapies comprising apremilast and Tyk2 inhibitors
US5212176A (en) R(+)-terazosin
RU2316318C2 (ru) Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
KR101459168B1 (ko) 수면 및 인지 관련 우울증에서의 통증 또는 잔여 증상의 치료를 위한, 세로토닌 재흡수, ５-ｈｔ３ 및 ５-ｈｔ１ａ 활성을 갖는 화합물인 1-[2-(2,4-디메틸페닐술파닐)페닐]피페라진
KR102303052B1 (ko) Jak 저해제를 포함하는 제약 조성물
CN101347427A (zh) 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方
AU1732999A (en) Method of treating heart failure
CN104066324A (zh) 治疗痛风急性发作的方法
JP2001302514A (ja) フェニルエテンスルホンアミド誘導体含有医薬
KR101747486B1 (ko) 동통 치료제
DK162999B (da) Imidazoquinazolinforbindelse samt fremgangsmaade til fremstilling deraf
ZA200106439B (en) Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity.
EP3890737B1 (en) Usp19 inhibitors for use in a method of treating obesity, insulin resistance and type ii diabetes
WO2020078445A1 (zh) 一种治疗纤维化疾病的药物组合或药物组合物
JP6775699B2 (ja) インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法
CN112535686B (zh) 激酶抑制剂的新用途
CN115243774B (zh) 含氨氯地平、氯噻酮和阿米洛利的药物组合物
WO2021224494A1 (en) New treatments of viral infections
JP5559696B2 (ja) 糖尿病性腎症の治療剤
JP2023522444A (ja) サイトカインストーム症候群を治療するためのジアジンおよびトリアジン化合物
EP0591937A1 (en) Use of isoquinolinone derivatives for treating hyperlipoproteinemia
CN101361736A (zh) 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方
CN101043882A (zh) 肽化合物治疗骨癌疼痛、化学疗法－和核苷－诱导的疼痛的新用途